Life Sciences Tools and Services
Company Overview of Crown Bioscience, Inc.
Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...
3375 Scott Boulevard
Santa Clara, CA 95054
Founded in 2006
Key Executives for Crown Bioscience, Inc.
Co-Founder and Chief Executive Officer
Senior Vice President of Operation and General Manager of Crownbio Taicang Facility
Compensation as of Fiscal Year 2015.
Crown Bioscience, Inc. Key Developments
Crown Bioscience Offers Unique Immuno-Oncology Translational Research Platform
Nov 18 15
Crown Bioscience provides a comprehensive immuno-oncology translational research platform. Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer immunotherapies and move the best candidates forward to clinical trials. Crown’s in vitro immuno-oncology assays, including immunophenotyping and immuno-functional assays, help scientists validate immuno-oncology targets, screen for immuno-modulating agents, understand mechanisms of actions and identify biomarkers. With one of the world’s large collections of validated in vivo syngeneic cell line models, as well as primary allografts of tumors, Crown helps scientists evaluate and understand novel anticancer compounds. Crown also provides various humanized immuno-oncology in vivo models, including the MiXeno™ platform of transient human immunity by mixing human peripheral blood mononucleated cells (PBMC) with xenograft models for testing human biological-based immunotherapeutics for cancers, providing a simple, cost-effective alternative to full hematopoietic stem cell reconstitution. Crown’s other humanized immuno-oncology technologies under development include HuGEMM with knocked-in human checkpoint targets, e.g., huPD1 and huCTLA4, into immunocompetent models and PDX in human hematopoietic stem reconstituted models, both of which will be extremely valuable in evaluating human biologicals for immunotherapies.
Crown Bioscience Inc. Announces Executive Appointments
Oct 20 15
Crown Bioscience Inc. named Tetsuya Totsuka, Ph.D. as manager of business development for Japan. Before joining Crown Bioscience, Totsuka was director and COO of business development for a Tokyo-based biotech firm and director of the original developer of disparity mutagenesis technology for the improvement and breeding of useful organisms, including microorganisms, cultured cells, plants and animals. Mayet Pantastico will be the director of business development for Australia, Singapore, New Zealand and Korea. With more than 14 years of experience in sales and business development in the pharmaceutical industry, she was most recently sales and marketing manager in the Asia-Pacific region for a preclinical CRO focused on oncology models and GLP toxicology studies.
Crown Bioscience Enters an Exclusive Preclinical Services Alliance Utilizing the Collection of Naturally Occurring Diabetic Translational Models
Oct 14 15
Crown Bioscience announced that it has entered an exclusive preclinical services alliance utilizing the collection of naturally occurring diabetic translational models. The models are designed for research involving cardiovascular and metabolic diseases, including spontaneous developed diabetes and its complications, such as diabetic nephropathy, left ventricular diastolic dysfunction, fatty liver, diet-induced dyslipidemia, etc. They were developed to mirror aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced glucose disposition, insulin resistance and late stage insulin dependency.
Similar Private Companies By Industry
Recent Private Companies Transactions